Boston, Mass and Copenhagen, Demark. PerkinElmer Inc. announced plans to collaborate with BioImage to develop cell-based assays on the PerkinElmer EnVision(tm) HTS multilabel plate reader platform. The commercial terms of the collaboration were not disclosed. Based in Denmark, BioImage is a leader in using protein translocation based technology to identify novel therapeutics. The collaboration combines the BioImage assay technology with the PerkinElmer EnVision detection platform to develop a series of cell based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer's EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it the ideal detection platform for the BioImage assays. This powerful combination enables customers to perform robust cell based identification of inhibitors of protein/protein interactions at throughput levels previously not available. "As a leader in high-content screening and cell-based assay development, BioImage has an excellent skill base and holds a strong IP position in this space," said Peter Coggins, Ph.D., president, PerkinElmer Life and Analytical Sciences. "This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the HTS market," said Dr. Patrik Dahlén, CEO of BioImage. "We are actively out-licensing our IP estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many bio-pharmaceutical companies."
PerkinElmer to Acquire In-Vitro Diagnostics Company
PerkinElmer, Inc. and Immunodiagnostic Systems Holdings PLC (IDS) announced that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million). The transaction has a total enterprise value of ap ... more
PerkinElmer Completes Acquisition of Oxford Immunotec
PerkinElmer, Inc. announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tubercul ... more
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
PerkinElmer, Inc. announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ... more
Fisher Biosciences strengthens its reagent portfolio through acquisition of BioImage
Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics business. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science m ... more
